Delta-9-tetrahydrocannabinol/Cannabidiol, THC/CBD (Sativex®) which is indicated as treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis (MS) who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity related symptoms during an initial trial of therapy.
|05/12/2012||04/01/2013||Full Pharmacoeconomic Assessment Recommended|
|11/07/2014*||26/09/2014||Reimbursement Not Recommended|
*Formal assessment commenced following legislative changes.
The NCPE does not recommend reimbursement of Sativex® at the submitted price.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/02/2018|
|Rapid review completed||03/04/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of Sativex® compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||20/04/2018|
|Pre-submission consultation with Applicant||25/09/2018|
|Current status||Awaiting submission from Applicant|
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.